Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  capecitabine
Find trials that include:  Any drugs shown
Results 1-25 of 61 for your search:
Start Over
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0848, NCI-2011-01987, CDR0000659092, NCT01013649
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NL36315.042.11, NCI-2014-01600, 2010-023957-12, NCT01558921
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15372, NCI-2015-00221, 2014-002240-40, I4T-MC-JVCU, NCT02314117
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-062, NCI-2015-01332, 163187, 2015-000972-88, NCT02494583
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 153082, 2015-001020-27, NCT02555657
Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: EMR 100070-007, NCI-2016-00646, 2015-003300-23, NCT02625610
Capecitabine and Ziv-Aflibercept in Treating Patients with Refractory Solid Tumors or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00037688, NCI-2013-00472, NCT01661972
Phase Ib/II trial using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer with CNS Metastasis
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-US B09, NCI-2013-00082, 12-001358-CR-00003, CRAD001JUS182T, NCT01783756
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Quinacrine Hydrochloride and Capecitabine in Treating Patients with Metastatic or Recurrent Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: GI-078, NCI-2016-00139, NCT01844076
Cyclodextrin-Based Polymer-Camptothecin CRLX10, Capecitabine, and Radiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1315, NCI-2014-00897, NCT02010567
Gemcitabine Hydrochloride, Docetaxel, Capecitabine, Cisplatin, and Irinotecan Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: J14161, NCI-2015-00235, NCT02324543
Tosedostat and Capecitabine in Treating Patients with Pancreatic Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201503074, NCI-2015-00425, NCT02352831
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Hydroxychloroquine, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 070806, NCI-2012-00527, CINJ-070806, NCT01006369
Capecitabine, Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Stage II-III Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAD6491, NCI-2010-00829, NCT01065870
Proton or Photon Beam Radiation Therapy, Capecitabine, and Hydroxychloroquine in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-073, NCI-2012-00148, NCT01494155
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Bevacizumab, Capecitabine, and Temozolomide in Treating Patients with Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NET0012, NCI-2011-03497, 22412, END0012, SU-10282011-8571, NCT01525082
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOG301, NCI-2012-00660, 2010-022164-12, NCT01573468
Start Over